Related Experiment Video

Updated: May 29, 2026

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

Targeting several CAG expansion diseases by a single antisense oligonucleotide

Melvin M Evers1, Barry A Pepers, Judith C T van Deutekom

  • 1Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Plos One
|September 13, 2011
PubMed

Insights

Researchers developed a novel antisense oligonucleotide therapy to reduce toxic protein aggregates in Huntington's disease. This treatment also shows promise for other polyglutamine expansion disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington's disease is a fatal neurodegenerative disorder caused by expanded CAG repeats in the HTT gene.
  • The expanded polyglutamine tract leads to toxic protein aggregation, driving disease pathology.
  • Currently, no effective therapies exist for Huntington's disease.

Purpose of the Study:

  • To investigate the therapeutic potential of modified antisense oligonucleotides (ASOs) targeting expanded polyglutamine repeats.
  • To assess the efficacy of ASOs in reducing mutant huntingtin transcript and protein levels.
  • To explore the applicability of this ASO approach to other polyglutamine expansion disorders.

Main Methods:

  • Utilized modified 2'-O-methyl phosphorothioate (CUG)n triplet-repeat antisense oligonucleotides.
  • Tested ASO efficacy in patient-derived fibroblasts and lymphoblasts for Huntington's disease.
  • Evaluated ASO impact on mutant ataxin-1, ataxin-3, and atrophin-1 mRNA levels in related disorders.

Main Results:

  • A specific ASO, (CUG)(7), effectively reduced mutant huntingtin transcript and protein in Huntington's disease cells.
  • The (CUG)(7) ASO also decreased mutant ataxin-1 and ataxin-3 mRNA levels.
  • This ASO demonstrated efficacy in reducing atrophin-1 in dentatorubral-pallidoluysian atrophy cells.

Conclusions:

  • Modified antisense oligonucleotides represent a promising therapeutic strategy for Huntington's disease.
  • The developed ASO therapy shows potential for treating a range of polyglutamine expansion disorders.
  • This research opens new avenues for tackling neurodegenerative diseases caused by repeat expansions.

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...